Johnson & Johnson $JNJ Stock Acquired by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 54.2% in the third quarter, Holdings Channel.com reports. The firm owned 6,692 shares of the company’s stock after purchasing an additional 2,351 shares during the quarter. Contravisory Investment Management Inc.’s holdings in Johnson & Johnson were worth $1,772,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the period. Amundi grew its holdings in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Jupiter Topco LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $1,967,399,000. Finally, Janus Henderson Group PLC grew its holdings in shares of Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Morgan Stanley boosted their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. TD Cowen upped their price target on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Bank of America reaffirmed a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson Stock Down 5.6%

Shares of Johnson & Johnson stock traded down $14.83 during trading hours on Tuesday, reaching $248.90. 16,613,205 shares of the company’s stock were exchanged, compared to its average volume of 7,994,569. The company has a 50 day moving average of $266.01 and a two-hundred day moving average of $249.31. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $599.83 billion, a P/E ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. Johnson & Johnson’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 11.18 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

Insider Buying and Selling

In other news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.